93Z Stock Overview
A biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Marinomed Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €15.30 |
| 52 Week High | €30.80 |
| 52 Week Low | €2.60 |
| Beta | -0.038 |
| 1 Month Change | 39.73% |
| 3 Month Change | 77.91% |
| 1 Year Change | -48.83% |
| 3 Year Change | -83.00% |
| 5 Year Change | -84.70% |
| Change since IPO | -79.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 93Z | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.6% | 1.7% | 0.3% |
| 1Y | -48.8% | -16.3% | 6.9% |
Return vs Industry: 93Z underperformed the German Pharmaceuticals industry which returned -16.3% over the past year.
Return vs Market: 93Z underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| 93Z volatility | |
|---|---|
| 93Z Average Weekly Movement | 14.4% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 93Z's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 93Z's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 44 | Andreas Grassauer | www.marinomed.com |
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. The company operates through Virology, Immunology, and Other segments. Its products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections.
Marinomed Biotech AG Fundamentals Summary
| 93Z fundamental statistics | |
|---|---|
| Market cap | €25.42m |
| Earnings (TTM) | -€6.87m |
| Revenue (TTM) | €6.60m |
3.9x
P/S Ratio-3.7x
P/E RatioIs 93Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 93Z income statement (TTM) | |
|---|---|
| Revenue | €6.60m |
| Cost of Revenue | €6.19m |
| Gross Profit | €411.30k |
| Other Expenses | €7.28m |
| Earnings | -€6.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Apr 16, 2025
| Earnings per share (EPS) | -4.05 |
| Gross Margin | 6.23% |
| Net Profit Margin | -103.99% |
| Debt/Equity Ratio | -183.6% |
How did 93Z perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 14:34 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Marinomed Biotech AG is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Norbert Kalliwoda | Dr. Kalliwoda Research |
| Vladimira Urbankova | Erste Group Bank AG |
| Christian Ehmann | FMR - Frankfurt Main Research AG |